Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences develops neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. Its news commonly centers on EB-003, a lead candidate from the EVM301 Series designed to promote neuroplasticity without hallucinogenic effects and to modulate 5-HT2A and 5-HT1B receptors. Company updates also discuss preclinical models tied to PTSD, depression, anxiety and related neuropsychiatric conditions.
Recurring announcements include intellectual-property activity for the EVM301 and EVM401 Series, trademark registrations, corporate and financial results, and capital actions involving common stock, pre-funded warrants and other warrants. Enveric also reports business-development and conference activity around non-hallucinogenic and psychedelic-inspired therapeutic approaches.
Enveric Biosciences (NASDAQ: ENVB) welcomed the U.S. FDA’s finalized guidance on clinical investigations of psychedelic and psychedelic‑inspired therapeutics, noting that the document highlights issues such as functional unblinding, patient monitoring, abuse potential, repeat dosing, and the role of psychotherapy. According to Enveric, these are the same challenges that shaped the design of its neuroplastogenic candidate EB-003, which is intended to engage neuroplasticity-related receptor signaling associated with classic psychedelics while avoiding a hallucinogenic experience.
Enveric believes that, if EB-003’s non-hallucinogenic profile is confirmed in clinical studies, it may allow more conventional blinded trial designs and support a simpler outpatient treatment model. The FDA guidance also encourages early sponsor engagement and the use of modeling and other new approach methodologies to help evaluate safety and abuse potential, which Enveric views as relevant to purpose-designed molecules like EB-003. The FDA separately announced a September 14, 2026 Part 15 public hearing on the practical delivery of psychedelic therapies. Enveric’s planned Phase 1 program for EB-003 is designed to assess safety, tolerability, pharmacokinetics, subjective effects, and pharmacodynamic biomarkers after single and repeat dosing, with later patient studies to evaluate efficacy and durability.
Enveric Biosciences (NASDAQ: ENVB) will participate in the B. Riley Securities Mind, Muscle & Vision Summit on July 16, 2026, in Boston.
CEO Joseph Tucker, Ph.D., will join a Neuropsychiatry Fireside Chat highlighting neuropsychiatry trends, mental health drug development, and Enveric’s neuroplastogen EB-003. Management will also host one-on-one investor meetings.
Enveric Biosciences (NASDAQ: ENVB) will participate in the 2026 BIO International Convention, held June 22-25, 2026, in San Diego, California.
The company highlights recent positive preclinical phototoxicity results and the start of IND-enabling GLP genotoxicity studies for EB-003, which are expected to support an eventual IND submission and potential Phase 1 clinical entry. Enveric’s management will host meetings with potential strategic partners, and registered attendees can request meetings via the BIO One-on-One Partnering platform.
Enveric Biosciences (NASDAQ: ENVB) will participate in the UBS 3rd Virtual CNS Day on June 15, 2026. Company management plans one-on-one meetings with registered investors to discuss its business and clinical development strategy, recent corporate achievements, and anticipated milestones in psychiatric and neurological therapeutics.
Enveric Biosciences (NASDAQ: ENVB) has initiated IND-enabling genotoxicity studies for its lead neuroplastogen candidate, EB-003, a small-molecule therapeutic for psychiatric and neurological disorders.
The GLP studies, following ICH S2(R1) guidelines, include Ames and Micronucleus assays and support a potential future Phase 1 first-in-human trial.
Enveric Biosciences (NASDAQ: ENVB) reported positive preclinical in vitro phototoxicity results for lead neuroplastogen EB-003. Testing showed no photoreactive potential, reducing safety concerns for chronic treatment of neuropsychiatric disorders, including depression, anxiety and PTSD. This marks a further preclinical safety milestone as Enveric prepares for first-in-human Phase 1 trials.
Enveric Biosciences (NASDAQ: ENVB) reported first quarter 2026 results and a corporate update. Net loss attributable to stockholders was $1.6 million (loss/share $1.08) versus $2.2 million (loss/share $14.58) a year earlier, with $4.9 million cash at March 31, 2026.
The company advanced lead candidate EB-003 through IND-enabling studies and reported preclinical data showing dual Gq and β-arrestin 5-HT2A signaling and reduced conditioned fear in a PTSD model. Enveric strengthened its IP portfolio, noted withdrawal of a Post-Grant Review petition relating to patents tied to bretisilocin (GM-2505), and enhanced EVM301 coverage.
Enveric raised $2.8 million in Q1 offerings, followed by a private placement of up to $13.9 million (including $5 million upfront) and $1.5 million from warrant exercises, bringing cash to about $10.3 million as of May 15, 2026, which it believes funds operations into Q1 FY 2027.
Enveric Biosciences (NASDAQ: ENVB) announced issuance of US Patent No. 12,605,361 for methods of treating psychiatric disorders using its EVM301 Series carboxylated psilocybin derivatives. The April 21, 2026 patent broadens protection for tryptamine-based drug candidates and supports development of lead candidate EB003 targeting depression and anxiety.
Enveric Biosciences (NASDAQ: ENVB) highlighted preclinical results for EB-003, a dual 5-HT2A/5-HT1B modulator. A single dose significantly reduced context-induced freezing behavior one hour post-dose (p < 0.05), indicating a rapid reduction in conditioned fear in a validated PTSD model.
The company positioned EB-003 as a next-generation neuroplastogen targeting neuroplasticity and mood signaling pathways as interest in psychedelic-inspired therapies grows.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) appointed Joseph Tucker, Ph.D., CEO of Enveric Biosciences (NASDAQ: ENVB), to its Board of Directors on April 28, 2026. The appointment follows Lakewood-Amedex's recent Nasdaq direct listing and is positioned to strengthen governance and strategic capabilities as the company advances its Bisphosphocin® program, including lead candidate Nu-3 for infected diabetic foot ulcers.
Dr. Tucker brings more than two decades of biotech leadership, experience with public listings, M&A, and capital raises, including having raised over $100 million and advancing Enveric's EB-003 toward an anticipated first-in-human trial.